| Literature DB >> 26864699 |
Amar Oedit1, Rawi Ramautar1, Thomas Hankemeier1, Petrus W Lindenburg1.
Abstract
Electroextraction (EE) and electromembrane extraction (EME) are sample preparation techniques that both require an electric field that is applied over a liquid-liquid system, which enables the migration of charged analytes. Furthermore, both techniques are often used to pre-concentrate analytes prior to analysis. In this review an overview is provided of the body of literature spanning April 2012-November 2015 concerning EE and EME, focused on hyphenation to analytical techniques. First, the theoretical aspects of concentration enhancement in EE and EME are discussed to explain extraction recovery and enrichment factor. Next, overviews are provided of the techniques based on their hyphenation to LC, GC, CE, and direct detection. These overviews cover the compounds and matrices, experimental aspects (i.e. donor volume, acceptor volume, extraction time, extraction voltage, and separation time) and the analytical aspects (i.e. limit of detection, enrichment factor, and extraction recovery). Techniques that were either hyphenated online to analytical techniques or show high potential with respect to online hyphenation are highlighted. Finally, the potential future directions of EE and EME are discussed.Entities:
Keywords: Bioanalytical applications; Electroextraction; Electromembrane extraction; Hyphenation; Sample preparation
Mesh:
Substances:
Year: 2016 PMID: 26864699 PMCID: PMC5071742 DOI: 10.1002/elps.201500530
Source DB: PubMed Journal: Electrophoresis ISSN: 0173-0835 Impact factor: 3.535
Overview of EE and EME hyphenated to LC. EF and ER values indicated in italics are calculated based on data provided in the paper
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||||||
|
| EE | online | MS | Urine | stearoylcarnitine, hexanoylcarnitine, acetylcarnitine |
| 175–970 |
| 0.1 | 0.1 | 6 | 30 | 15000 |
|
| EE | online | MS | Plasma | angiotensin 2, angiotensin 1, angiotensin 2 (3‐8) | 10‐50 | ±570–990 |
| 0.1 | 0.1 | 6 | 40 | 15000 |
|
| EE | offline | MS | Urine | lauroylcarnitine, octanoylcarnitine, hexanoylcarnitine | 0.3–2 | 34–80 | 46–108 | 0.5 | 13.4 | 10 | 31 | 300 |
| [60] | EME | offline | UV | Environmental samples | Cr(IV) and Cr(III) | 54‐100 | 21.8‐33 | 31‐47 | 2.1 | 30 | 9 | 15 | 30 |
|
| EME | offline | UV | Academic | Azo red dye 46, 51 and 18 | 0.75‐1.8 | 96‐162 | 48‐81 | 6 | 30 | 20 | 12 | 60 |
|
| EME | offline | UV | 24 | 10 | 20 | 12 | 100 | |||||
| Plasma | naltrexone, nalmefene | 2.9 | 100‐199 |
| |||||||||
| Urine | naltrexone, nalmefene | 2.9 | 130‐140 |
| |||||||||
|
| EME | offline | UV | Academic | histidine, phenylalanine, tryptophan | 32‐146 |
| 7.1‐21.6 | 2.5 | 15 | 20 | 10 | 100 |
| [61] | EME | offline | UV | Academic | 2.5 | 15 | n.r. | 30‐250 | |||||
| amitriptyline, nortriptyline | 1.8‐3.8 |
| 89‐96 | 14.5 | |||||||||
| diclofenac, mefenamic acid | 6.8‐8.3 |
| 44‐53 | 10 | |||||||||
| terbutaline, salbutamol | 4.4‐10 |
| 66‐83 | 20 | |||||||||
|
| EME | offline | UV | Gelatin | asparagine, glutamine | 189‐342 | 29‐53 | 43‐79 | 2.5 | 15 | 20 | 20 | 137 |
|
| EME | offline | UV | Urine | nalmefene, diclofenac | 5.9‐14 | 300‐350 | 12.5‐14.6 | 24 | 10 (×2) | 14 | 12 | 40 |
|
| EME | offline | UV | 24 | 25 | 20 | 10 | 100 | |||||
| Plasma | betaxolol, atenolol | 33‐38 | 86‐245 |
| |||||||||
| Urine | betaxolol, atenolol | 6.5‐7.5 | 69‐236 |
| |||||||||
|
| EME | offline | UV | Urine | strychnine, brucine | 6.9‐21 | 114‐122 |
| 3 | 10 | 10 | 13 | 1.5 |
| [62] | EME | offline | UV | Academic | verapamil, clomipramine, | 7.2‐15 | n.r. | n.r. | 7 | 25 | 20 | 15 | 200 |
| Urine | trimipramine | 129–256 | 42.6‐84.2 | ||||||||||
| Wastewater | 115–259 | 38.0‐85.3 | |||||||||||
| [63] | EME | offline | UV | melamine | 6.5 | 20 | 15 | 10 | 90 | ||||
| Milk | 38 | 85 | 59 | ||||||||||
| Powder milk | 46 | 82 | 92 | ||||||||||
| Water | 16 | 192 | 85 | ||||||||||
| [64] | EME | offline | UV | Academic | 2.1 | 30 | 5 | n.r. | 20 | ||||
| diclofenac | 5.1 | 59 | 84.3 | ||||||||||
|
| EME | offline | UV | Urine | nortriptyline, amitryptiline | 11‐14 | 17‐18 | 34‐36 | 1 | 20 | 33.3 | 15 | 40 |
| [65] | EME | offline | UV | Urine | nortryptiline, amitryptiline | 1.9‐3.6 | 89‐94 | 11.6‐12.5 | 30 | 40 | 20 | 12 | 100 |
| Plasma | amitryptiline, nortryptiline | 1.8‐1.9 | 83–92 | 11.1‐12.3 | |||||||||
|
| EME | offline | 10 | 30 | 15 | 15 | 50 | ||||||
| UV | Academic | fluoroquinolones | 0.039‐0.22 | 40‐85 |
| ||||||||
| FLD | Academic | fluoroquinolones | 0.014‐0.10 | 40‐85 |
| ||||||||
| [66] | EME | offline | Academic | 10 | 50 | 7 | 12 | 10 | |||||
| UV | basic drugs | 0.17‐6.6 | 51‐86 |
| |||||||||
| FLD | naproxen, salicylic acid, ibuprofen | 0.0026‐3.5 | |||||||||||
|
| EME | offline | CD | Academic | chloride, nitrate, fluoride, nitrite, bromide, sulfate, phosphate | 17‐79 | 67‐117 |
| 5 | 30 | 10 | 14 | 15 |
|
| EME + LPME | offline | UV/MS | Plasma | ketoprofen, ibuprofen, citaprolam, sertraline | 0.79‐6.2 |
| 63‐95 | 0.6 | 100 | 15 | 6.1 (UV) 17 (MS) | 300 |
|
| EME | offline | MS | Whole blood | basic drugs | 0.16‐15 |
| 9‐28 | 0.08 | 10 | 5 | 5.5 | 15 |
| [67] | EME | offline | MS | Dried bloodspots | methadone, nortriptyline, pethidine |
|
| 83‐95 | 1 | 19 | 25 | 26 | 100 |
|
| EME | offline | MS | Dried bloodspots | citaprolam, methadone, loperamide, sertraline | 1.2‐17 |
| 44‐115 | 0.3 | 21 | 10 | 24 | 100 |
| [68] | EME | offline | MS | Saliva | basic drugs | 2.3‐46 |
| 10‐65 | 0.3 | 25 | 5 | 20 | 15 |
|
| EME | offline | MS | Academic standards | quetiapine, amitriptyline, fluoxetine, sertraline | 0.052‐0.91 |
| 15‐33 | 0.24 | 70 | 8 | 18 | 200 |
|
| EME | offline | MS | Dried urine spots | Volatile organic compound metabolites | 5.0‐388 | 13.2‐27.6 | 33.0‐69.1 | 1 | 25 | 20 | 5 | 200 |
|
| EME | offline | MS | Urine | Volatile organic compound metabolites | 1.3‐33.3 | 11 ‐ 16 | 52.8‐70.7 | 0.8 | 40 | 15 | 4 | 300 |
|
| EME | online | MS | River water | Chlorinated phenoxyacetic acids | 0.12‐0.43 | 201‐235 |
| 5 | 20 | 25 | 28 | 200 |
1matrix is only mentioned when extraction performance is tested therein.
*in order of increasing LOD.
**danofloxacin, enrofloxacin, marbofloxacin, ciprofloxacin, grepafloxacin, gatifloxacin.
***danofloxacin, enrofloxacin, grepafloxacin, ciprofloxacin, norfloxacin, gatifloxacin, marbofloxacin.
****N‐acetyl‐s‐(phenyl)‐l‐cysteine, N‐acetyl‐s‐benzyl‐l‐cysteine, N‐acetyl‐S‐(2,2dichlorovinyl)‐l‐cysteine, N‐acetyl‐S‐(2,2dichlorovinyl)‐l‐cysteine, N‐acetyl‐S‐(1,2dichlorovinyl)‐L‐cysteine, 3‐methylhippuric acid, 4‐methylhippuric acid, 2‐methylhippuric acid, phenylglyoxylic acid, hippuric acid, mandelic acid.
#naproxen, ketoprofen, ketorolac, salicylic acid, diclofenac, ibuprofen.
##Ketamine, 3,4‐methylenedioxy‐metamphetamine, metamphetamine, cathinone, 2,5‐dimethoxy‐4‐iodoampetamine, 3,4‐methylenedioxy‐amphetamine.
###methadone, buprenorphine, para‐methoxyamphetamine, methamphetamine, para‐methoxymetamphetamine.
####trichlorophenoxyacetic acid, 3,4‐dichlorophenoxyacetic acid, 2,4‐dichlorophenoxyacetic acid, chlorophenoxyacetic acid.
#####N‐acetyl‐s‐(phenyl)‐l‐cysteine, 2‐methylhippuric acid, 3‐methylhippuric acid, 4‐methylhippuric acid, hippuric acid, phenylglyxolic acid.
n.r., not reported; n.a., not applicable; Ref., reference, Tech., technique, Hyph., hyphenation, Det., detection, EF, enrichment factor; ER, extraction recovery; ET, extraction time; ST, separation time; EV, extraction voltage.
Figure 1(A) Experimental setup of the developed EME‐LC‐MS system (B) EME‐LC‐MS results of CPAs spiked to river water (extraction voltage 200 V, donor phase flow rate 0.2 mL/min). (a) 5 mL of 0.5 ng/mL CPAs (b) 10 mL of 0.25 ng/mL CPAs and (c) 25 mL of 0.1 ng/mL CPAs. Note that for each experiment the total amount of CPAs was the same. 4‐CPA = chlorophenoxyacetic acid; 3,4‐D = 3,4‐dichlorophenoxyacetic acid; 2,4‐D = 2,4‐dichlorophenoxyacetic acid; 2,4,5‐T = trichlorophenoxyacetic acid. Adapted from 23.
Figure 2(A) Valve setup for interfacing large volume cEE with LC. (a) inlet capillary, (b) EE capillary, (c) sample loop, (d) outlet capillary, (e) LC waste, (f) LC pump tubing, (g) tubing to earth, (h) tubing to LC‐MS. Step 1: situation after all phases have been loaded. The grey zone in the EE‐capillary depicts the organic phase with analytes. Before EE starts, the valve is switched. Step 2: situation after EE is finished; the small black zone depicts the concentrated analytes. Step 3: situation after the sample has been transferred into the sample loop by applying pressure. After sample transfer, the valve is switched back. Step 4: situation where the sample zone is being injected into the LC‐MS system. (B) comparison of chromatograms obtained from LC (0.1 μL injection) and large volume cEE‐LC‐MS (100 μL extraction volume). The initial peptide concentration was equal and ERs. Adapted from 28.
Overview of EME hyphenated to GC. EF and ER values indicated in italic are calculated based on data provided in the paper
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||||||
|
| EME | offline | FID | 2.1 | 7 | 20 | 5 | 200 | |||||
| Plasma | imipramine, clopramine | 1.7‐2.5 | 215‐250 | 72 | |||||||||
| Urine | 1.4‐2.4 | 240‐265 | 81 | ||||||||||
|
| EME‐DLLME | offline | FID | Urine | quinoline, 2,4‐lutidine, 3‐methylpyridine, 4‐dimethylaminopyridine | 1.9‐16 | 40‐202 |
| 24 | 10 | 20 | 10 | 50 |
|
| EME‐SPME | offline | FID | Plant tissue | 2,4‐dichlorophenoxyacetic acid, 2‐methyl‐4‐chlorophenoxyacetic acid | 2.3‐25 | n.a. | 0.6‐4.8 | 24 | n.a. | 20 | 12 | 50 |
|
| EME‐SPME | offline | FID | Urine | doxepin, amitriptyline | 3.6 | n.a. | 4.0‐10.4 | 24 | n.a. | 20 | 8 | 120 |
| Plasma | amitriptyline, doxepin | 9.0‐18 | n.a. | 5.9‐3.1 | |||||||||
|
| Two‐phase EME | offline | FID | Academic | methadone, alfentanil, sufentanil | 1.9‐3.6 |
| 70.5‐95.2 | 3 | 6 | 20 | 12.5 | 80 |
|
| EME‐SPME | offline | FID | 24 | n.a. | 20 | 8 | 120 | |||||
| Urine | doxepin, amitriptyline | 3.6 | n.a. | 4.0‐10.4 | |||||||||
| Plasma | amitriptyline, doxepin | 9.0‐18 | n.a. | 5.9‐3.1 | |||||||||
|
| Two‐phase EME | offline | MS | imipramine, citaprolam, sertraline, desipramine | 1.2 | 6 | 15 | 25 | 60 | ||||
| Academic | 0.36‐0.75 | 140‐175 | 70‐87 | ||||||||||
| Urine | n.r. | 145 |
| ||||||||||
|
| EME‐DLLME | offline | MS | 24 | 10 | 14 | 10 | 240 | |||||
| Urine | doxepin, amitriptyline, trimipramine | 11‐51 | 753‐781 |
| |||||||||
| Plasma | trimipramine, doxepin, amitriptyline | 10‐54 | 383‐397 |
|
1matrix is only mentioned when extraction performance is tested therein.
*in order of increasing LOD
Overview of EME hyphenated to CE. EF and ER values indicated in italic are calculated based on data provided in the paper
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||||||
|
| EME | online | UV | Urine | loperamide, methadone, haloperidol, nortryptiline, pethidine | 0.41‐60 | 25‐196 | 0.10‐0.79 | 0.2 | 0.008 | 2 | 25 | 200 |
|
| EME | offline | UV | Urine | drugs and amino acids | 2.1‐2500 |
| 0.20‐21.7 | 3.5 | 20 | 5 | 4 | ±4/±40 |
| [69] | EME | offline | UV | S‐and R‐propranolol | 4 | 20 | 32 | 19 | 40 | ||||
| Urine | 27 | 132‐134 | 66‐67 | ||||||||||
| Plasma | 39 | 108‐110 | 54‐55 | ||||||||||
| [70] | EME | offline | UV | 4 | 20 | 20 | 7 | 125 | |||||
| Hair | methadone, ephedrine, methamphetamine | 9.8‐41 | 116‐140 | 56‐64 | |||||||||
| Urine | methadone, methamphetamine, ephedrine | 4.9‐18 | 112‐128 | 58‐70 | |||||||||
| [71] | EME | offline | UV | Urine | thebaine, ibuprofen | 23‐24 | 150‐160 | 75‐80 | 4 | 20 | 25 | 10 | 40 |
|
| EME | offline | UV | 4 | 20 | 10 | 14 | 5 | |||||
| Acedemic | naproxen, ibuprofen | 4.3‐7.3 | 180‐188 | 90‐94 | |||||||||
| Plasma | n.r. |
| 69‐77 | ||||||||||
| Waste water | n.r. |
| 90‐92 | ||||||||||
| Breast milk | n.r. |
| 74‐78 | ||||||||||
| Urine | n.r. |
| 85‐88 | ||||||||||
|
| EME | offline | UV | Urine | buprenorfine | 2.1 | 185 | 92 | 4 | 20 | 15 | 10 | 200 |
| [72] | EME | offline | UV | 4 | 20 | 15 | 20 | 15 | |||||
| Academic | naproxen, diclofenac | 6.56‐8.17 | 176‐184 | 88‐92 | |||||||||
| Urine | diclofenac, naproxen | 15.3‐15.8 | 164–176 | 82–88 | |||||||||
| Plasma | diclofenac, naproxen | 19.7‐20.5 | 158–166 | 79–83 | |||||||||
| [73] | EME | offline | UV and C4D | Environmental water | chlorinated phenoxyacetic acids | ≤19‐≤39 |
| 15‐25 | 0.9 | 20 | 5 | 10 | 150 |
|
| EME | offline | C4D | Saliva | spermine, spermidine, cadaverine, putrescine | 8.4‐79 | 17 ‐ 106 |
| 7 | 8 | 20 | 22 | 10 |
| [74] | EME | offline | C4D | Plasma | 3,4‐methylenedioxy‐metamphetamine, amphetamine, metamphetamine | 5.2‐17 | 97‐103 | 65‐69 | 3 | 20 | 10 | 7 | 300 |
|
| EME | offline | C4D | 10 | 100 | 10 | 5.3 | 1500 | |||||
| Academic | glyphosphate, aminomethylphosphonic acid | 0.25‐0.58 | 87‐95 | 86‐96 | |||||||||
| River water | n.r. | 85‐95 | 85‐95 |
1matrix is only mentioned when extraction performance is tested therein.
*in order of increasing LOD.
**loperamide, haloperidol, nortriptyline, tryptophan, phenylalanine, creatinine, tyrosine, histidine, arginine.
***pentachlorophenol, 2,4,6‐trichlorophenol, 2,3‐dichlorophenol, 2,3‐dichlorophenol, 2‐chlorophenol, 3‐chlorophenol, 4‐chlorophenol.
****3,4‐methylenedioxy‐methamphetamine, amphetamine, methamphetamine.
#loperamide, methadone, nortriptyline, pethidine, haloperidol.
Figure 3(A) Instrumentation used for nano‐EME (B) urine analysis by CE‐UV, comparing (a) blank urine without nano‐EME, (b) spiked urine without nano‐EME and (c) spiked urine with nano‐EME, applying 200 V for only 15 s. Peak assignment: 1 pethidine, 2 nortriptyline, 3 methadone, 4 haloperidol, 5 loperamide. Adapted from 50.
Overview of EME hyphenated to direct detection
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |||||||
|
| EME | online | MS | Rat liver microsomes | amitriptyline, promethazine, imipramine | 29 | n.r. | n.r. | 1 | flowing | variable | n.a. | 2.5 |
|
| EME | online | MS | Rat liver microsomes | Amitriptyline | 140 | n.r. | 83 | 1 | flowing | variable | n.a. | 15 |
|
| Three‐phase EE | online | MS | Plasma | acylcarnitines | 90‐330 | 2 ‐ 7 |
| 0.05 | 2 | 9 | n.a. | 140 |
|
| EME | online | MS | Rat liver microsomes | amitriptyline, promethazine, methadone | n.r. | n.r. | n.r. | flowing | flowing | variable | n.a. | 200 |
|
| EME | offline | ED | Urine | Morphine | 5.3 | 152 | 76 | 4 | 20 | 24 | n.a. | 90 |
|
| EME | offline | FLD | Seawater | Uranium | 0.42 | 64.1‐88.1 |
| 2.5 | 20 | 14 | n.a. | 80 |
| [75] | EME‐SPME | offline | MS | Academic | mefenamic acid, ibuprofen | 0.17‐0.24 | n.r. | n.r. | 3 | n.a. | 24 | n.a. | 80 |
|
| EME | offline | UV | Waste water | Thorium | 1.2 | 50 |
| 10 | 20 | 30 | n.a. | 90 |
1matrix is only mentioned when extraction performance is tested therein.
*in order of increasing LOD.
**propionyl‐, octanoyl‐, butyryl‐, decanoyl‐ and hexanoylcarnitine.
***and their metabolites.
Figure 4(A) Schematic drawing of the dip‐in flow‐flow EME probe. (B) comparison of metabolic profiles of promethazine obtained with EME‐MS and LC‐MS. a) overlay of extracted ion chromatograms of promethazine (b) and its two main metabolites, S‐oxide promethazine (c) and S‐oxide OH‐promethazine (d). NADPH was added to the reaction mixture to initiate metabolism. RLM = rat liver microsome. Adapted from 19.
Figure 5(A) setup of three‐phase EE (left) and its coupling to nanoESI‐DI‐MS (right). (B) influence of the organic filter composition on analyte enrichment factor. EtoAc = ethyl acetate, MetoAc = methyl acetate, DEHP = bis(2‐ethylhexyl)phosphate. Adapted from 9.